Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Schnitt, T. Jacobs (2001)
Current status of HER2 testing: caught between a rock and a hard place.American journal of clinical pathology, 116 6
M. Coombes, Emma Ph.D., Lorna Ph.D., Robert M.Phil., Ph.D Jassem, Thierry Ph.D., Stephen M.D., Isabel M.D., M. Bertelli, Olaf M.D., Alan Ph.D., Emilio M.D., David M.D., M. Coleman, Lesley M.D., D.Phil, M. Mickiewicz, D.M.Sc Andersen, Per Lønning, Giorgio Ph.D., Alan Ph.D., Nick M.D., M.Sc Snowdon, Ph.D Carpentieri, M. Massimini, M.Sc Bliss (1977)
THE NEW ENGLAND JOURNAL OF MEDICINEThe Lancet, 309
R. Ridolfi, M. Jamehdor, J. Arber (2000)
HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization ApproachModern Pathology, 13
S. Wludarski, C. Bacchi (2008)
High Concordance of SP3 Rabbit Monoclonal Antibody With FISH to Evaluate HER2 in Breast CarcinomaApplied Immunohistochemistry & Molecular Morphology, 16
F. O'Malley, T. Thomson, J. Julian, Cherry Have, R. Cosby, K. Gelmon, I. Andrulis, T. Whelan (2008)
HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.Archives of pathology & laboratory medicine, 132 1
J. Barron, M. Cziraky, T. Weisman, David Hicks (2009)
HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.The oncologist, 14 8
Peter Birner, Georg Oberhuber, Josephine Stani, Cornelia Reithofer, H. Samonigg, H. Hausmaninger, Ernst Kubista, W. Kwasny, D. Kandioler-eckersberger, Michael Gnant, Raimund Jakesz (2001)
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 6
(2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2overexpressing metastatic breast cancer
PH.D. YOUDEN (1950)
Index for rating diagnostic testsCancer, 3
(2009)
The HER2 receptor and breast cancer: ten years of targeted anti-HER2 therapy and personalized medicine
E. Rossi, A. Ubiali, M. Cadei, P. Balzarini, E. Valagussa, L. Lucini, F. Alpi, A. Galletti, Lucia Fontana, C. Tedoldi, P. Grigolato (2006)
HER-2/neu in Breast Cancer: A Comparative Study Between Histology, Immunohistochemistry, and Molecular Technique (FISH)Applied Immunohistochemistry & Molecular Morphology, 14
K. Tedesco, A. Thor, David Johnson, Y. Shyr, K. Blum, L. Goldstein, W. Gradishar, B. Nicholson, D. Merkel, D. Murrey, S. Edgerton, G. Sledge (2004)
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 6
L. Lago, V. Durbecq, C. Desmedt, R. Salgado, T. Verjat, L. Lespagnard, Yan Ma, I. Veys, A. Leo, C. Sotiriou, M. Piccart, D. Larsimont (2006)
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancerMolecular Cancer Therapeutics, 5
M. Press, G. Hung, W. Godolphin, D. Slamon (1994)
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.Cancer research, 54 10
D. Gancberg, L. Lespagnard, G. Rouas, M. Paesmans, M. Piccart, A. Leo, J. Nogaret, D. Hertens, A. Verhest, D. Larsimont (2000)
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.American journal of clinical pathology, 113 5
Kelly Young, R. Lewis (1997)
What is confidence? Part 2: Detailed definition and determination of confidence intervals.Annals of emergency medicine, 30 3
M. Bilous, M. Dowsett, W. Hanna, J. Isola, A. Lebeau, A. Moreno, F. Penault-Llorca, J. Rüschoff, G. Tomasic, M. Vijver (2003)
Current Perspectives on HER2 Testing: A Review of National Testing GuidelinesModern Pathology, 16
E. Perez, P. Roche, R. Jenkins, C. Reynolds, K. Halling, J. Ingle, L. Wold (2002)
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.Mayo Clinic proceedings, 77 2
W. Powell, D. Hicks, Nichole Prescott, S. Tarr, Simas Laniauskas, T. Williams, S. Short, J. Pettay, R. Nagle, D. Dabbs, K. Scott, Richard Brown, T. Grogan, P. Roche, R. Tubbs (2007)
A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory ReproducibilityApplied Immunohistochemistry & Molecular Morphology, 15
P. Roche, V. Suman, R. Jenkins, N. Davidson, S. Martino, P. Kaufman, F. Addo, B. Murphy, J. Ingle, E. Perez (2002)
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.Journal of the National Cancer Institute, 94 11
M. Cobleigh, C. Vogel, D. Tripathy, N. Robert, S. Scholl, L. Fehrenbacher, J. Wolter, V. Paton, S. Shak, G. Lieberman, D. Slamon (1999)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
Y. Yarden (2001)
Biology of HER2 and Its Importance in Breast CancerOncology, 61
(2006)
HER2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists
J. Kulka, A. Tőkés, P. Kaposi-Novák, N. Udvarhelyi, Anikó Keller, G. Lotz, Z. Schaff (2006)
Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR — A comparison with immunohistochemical and FISH resultsPathology & Oncology Research, 12
M. Dowsett, J. Bartlett, I. Ellis, J. Salter, M. Hills, E. Mallon, A. Watters, T. Cooke, C. Paish, P. Wencyk, S. Pinder (2003)
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centresThe Journal of Pathology, 199
T. Jacobs, A. Gown, H. Yaziji, Melissa Barnes, S. Schnitt (1999)
Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
Antonio Wolff, M. Hammond, Jared Schwartz, K. Hagerty, D. Allred, Richard Cote, M. Dowsett, P. Fitzgibbons, Wedad Hanna, A. Langer, L. McShane, S. Paik, M. Pegram, Edith Perez, Michael Press, A. Rhodes, C. Sturgeon, S. Taube, R. Tubbs, Gail Vance, Marc Vijver, Thomas Wheeler, Daniel Hayes (2006)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Archives of pathology & laboratory medicine, 131 1
J. Reddy, J. Reimann, S. Anderson, P. Klein (2006)
Concordance between central and local laboratory HER2 testing from a community-based clinical study.Clinical breast cancer, 7 2
Y. Yarden, M. Sliwkowski (2001)
Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2
Instituto Brasileiro de Geografia e Estatı´stica web site
A. Gown (2008)
Current issues in ER and HER2 testing by IHC in breast cancerModern Pathology, 21
(1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER2/ neu oncogene
Ian Ellis, J. Bartlett, Mitchell Dowsett, S. Humphreys, Bharat Jasani, Keith Miller, Sarah Pinder, Anthony Rhodes, Rosemary Walker (2004)
Best Practice No 176Journal of Clinical Pathology, 57
G. Sauter, James Lee, J. Bartlett, D. Slamon, M. Press (2009)
Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
(1994)
Quantitative aspects of clinical reasoning
E. Perez, V. Suman, N. Davidson, S. Martino, P. Kaufman, W. Lingle, P. Flynn, J. Ingle, D. Visscher, R. Jenkins (2006)
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 19
M. Fornier, F. Esteva, A. Seidman (2000)
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.Seminars in oncology, 27 6 Suppl 11
(1999)
HER2/neu (c-erb-B2) gene and protein in breast cancer
A. Gown, L. Goldstein, T. Barry, S. Kussick, P. Kandalaft, Patricia Kim, C. Tse (2008)
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring systemModern Pathology, 21
M. Owens, B. Horten, M. Silva (2004)
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.Clinical breast cancer, 5 1
J. Hilden, P. Glasziou (1996)
Regret graphs, diagnostic uncertainty and Youden's Index.Statistics in medicine, 15 10
(2003)
HER 2 / neu testing of breast cancer patients in clinical practice
G. Pauletti, Suganda Dandekar, H. Rong, Lilllian Ramos, Hongjun Peng, Ram Seshadri, D. Slamon (2000)
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 21
Estimativa 2010 -Incideˆncia de caˆncer no Brasil
B. Vegt, G. Bock, J. Bart, Nick Zwartjes, J. Wesseling (2009)
Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancerModern Pathology, 22
(2005)
Diagnostic evaluation of HER2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials
R. Walker (2005)
World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital OrgansHistopathology, 46
M. Press, D. Slamon, K. Flom, Jinha Park, Jian‐Yuan Zhou, L. Bernstein (2002)
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 14
T. Leong, A. Leong (2006)
Controversies in the Assessment of HER-2: More Questions Than AnswersAdvances in Anatomic Pathology, 13
R. Ainsworth, J. Bartlett, J. Going, E. Mallon, A. Forsyth, J. Richmond, W. Angerson, A. Watters, B. Dunne (2005)
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest™ in breast carcinomaJournal of Clinical Pathology, 58
S. Paik, J. Bryant, E. Tan-chiu, E. Romond, W. Hiller, Kyeongmee Park, A. Brown, G. Yothers, S. Anderson, Roy Smith, D. Wickerham, N. Wolmark (2002)
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.Journal of the National Cancer Institute, 94 11
W. Hanna, F. O'Malley, P. Barnes, R. Berendt, L. Gaboury, A. Magliocco, Norman Pettigrew, S. Robertson, S. Sengupta, B. Têtu, Tom Thomson (2007)
Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancerCurrent Oncology, 14
H. Yaziji, L. Goldstein, T. Barry, R. Werling, H. Hwang, G. Ellis, J. Gralow, R. Livingston, A. Gown (2004)
HER-2 testing in breast cancer using parallel tissue-based methods.JAMA, 291 16
David Schwartz (1990)
A Hitchhiker’s Guide to the NIEHS Strategic PlanEnvironmental Health Perspectives, 114
S. Papadopoulos, G. Kouvatseas, D. Skarlos, N. Malamos, E. Delliou, Ioanna Saratsiotou, A. Ardavanis, D. Mavroudis, E. Skarpidi, P. Arapantoni, I. Karyda, Frideriki Patakioyta, G. Aravantinos, E. Razis, G. Fountzilas, P. Kosmidis (2007)
Comparison of HER2 detection methods between central and regional laboratories in Greece.Clinical breast cancer, 7 10
RESEARCH ARTICLE HER2 Testing in Breast Carcinoma Very Low Concordance Rate Between Reference and Local Laboratories in Brazil Sheila Cristina Lordelo Wludarski, MD,*w Lisandro Ferreira Lopes, MD, PhD,* Ta´cio R. Berto e Silva, MD,* Filomena M. Carvalho, MD, PhD,w Lawrence M. Weiss, MD,z and Carlos E. Bacchi, MD, PhD*w ERBB2. This receptor has tyrosine kinase activity and is Abstract: Breast cancer accounts for approximately one involved in cellular signaling that regulates cell growth 3,4 quarter of all cancers in females. HER2 gene amplification or and development. HER2 gene amplification or HER2 HER2 protein overexpression, detected in about 20% of breast protein overexpression, detected in approximately 20% carcinomas, predicts a more aggressive clinical course and of breast carcinomas, predicts a more aggressive clinical determines eligibility for targeted therapy with trastuzumab. course with a worse response to hormonal therapy and HER2 testing has become an essential part of the clinical determines eligibility for targeted therapy with the anti- evaluation of all breast carcinoma patients, and accurate HER2 HER2 monoclonal antibody called trastuzumab (Her- results are critical in identifying patients who may be benefited ceptin, Genentech Inc, South San Francisco, CA). For from targeted therapy. This study investigated the concordance these reasons,
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Mar 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.